A5004571816- Breast Cancer Treatment Studies
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Spinal Fractures and Fixation Techniques
- Spine and Intervertebral Disc Pathology
- Cancer-related molecular mechanisms research
- Cancer Diagnosis and Treatment
- Cervical and Thoracic Myelopathy
- Cancer, Lipids, and Metabolism
- BRCA gene mutations in cancer
- Cancer Risks and Factors
- Cancer Genomics and Diagnostics
- Nonmelanoma Skin Cancer Studies
- Gastrointestinal disorders and treatments
- Dermatologic Treatments and Research
- Cancer-related cognitive impairment studies
- Multiple and Secondary Primary Cancers
- Systemic Sclerosis and Related Diseases
- Genetic factors in colorectal cancer
- Cancer survivorship and care
- Health Systems, Economic Evaluations, Quality of Life
- Vascular Malformations and Hemangiomas
- Breast Implant and Reconstruction
- Breast Lesions and Carcinomas
Moffitt Cancer Center
2019
Northern Indiana Cancer Research Consortium
2019
Aurora Health Care
2019
Roswell Park Comprehensive Cancer Center
2019
Western Maryland Health System
2019
Cancer Genomics Centre
2019
The Netherlands Cancer Institute
2019
Loyola University Chicago
2019
Minnesota Oncology
2019
Western Pennsylvania Hospital
1993-2010
Abstract Objective The Exercise Program in Cancer and Cognition Study was a randomized controlled trial designed to determine whether 6 months of moderate‐intensity aerobic exercise improves neurocognitive function women with breast cancer (BC) receiving endocrine therapy (ET). Methods Postmenopausal hormone receptor+, early‐stage BC, within two years post‐primary were the intervention (six months, ≥150 min exercise/week) or usual care control condition. Outcomes assessed at...
Among patients who undergo the 21-gene assay (21-GA), 39% to 67% receive an intermediate risk result and may ambiguous treatment guidance. The 70-gene signature (70-GS) be associated with physicians' decisions in this population early breast cancer.To determine whether 70-GS findings are about adjuvant confidence their recommendations evaluate dichotomous (high- vs low-risk) continuous distribution of indices among group risk.The Prospective Study MammaPrint Breast Cancer Patients With...
The 80-gene molecular subtyping signature (80-GS) reclassifies a proportion of immunohistochemistry (IHC)-defined luminal breast cancers (estrogen receptor-positive [ER+], human epidermal growth factor receptor 2-negative [HER2-]) as Basal-Type. We report the association 80-GS reclassification with neoadjuvant treatment response and 5-year outcome in patients cancer.Neoadjuvant Breast Registry Symphony Trial (NBRST; NCT01479101) is an observational, prospective study that included 1,069...
Abstract Background The Neoadjuvant Breast Symphony Trial (NBRST) demonstrated the 70-gene risk of distant recurrence signature, MammaPrint, and 80-gene molecular subtyping BluePrint, precisely determined preoperative pathological complete response (pCR) in breast cancer patients. We report 5-year follow-up results addition to an exploratory analysis by age menopausal status. Methods observational, prospective NBRST (NCT01479101) included 954 early-stage patients aged 18–90 years who...
A case of vertebrobasilar transient ischemia and posterior cerebral infarction caused by a ruptured cervical disc is reported. The causes extrinsic vertebral artery compression are reviewed.
PURPOSE The prospective Neoadjuvant Breast Registry Symphony Trial compared the 80-gene molecular subtyping signature with clinical assessment by immunohistochemistry and/or fluorescence in situ hybridization predicting pathologic complete response (pCR) and 5-year outcomes patients early-stage breast cancer. METHODS Standard-of-care neoadjuvant chemotherapy combined trastuzumab or plus pertuzumab was given to human epidermal growth factor receptor 2 (HER2)–positive tumors (n = 295). pCR...
Women undergoing breast conservation therapy (BCT) for stage 1 cancer have adjuvant external beam radiotherapy (EBR). In addition, the use of brachytherapy radiation is being used. We present two local tumor recurrences review. Our first patient underwent BCT, sentinel lymph node biopsy (SLNBx) and MammoSite a T1N0M0 infiltrating ductal carcinoma (IDC) right breast. Pathology: 0.6 cm poorly differentiated ER, PR, Her-2/ Neu negative IDC. At 18 months, she had palpable axillary nodes. Fine...
As more patients with early-stage breast cancer receive neoadjuvant endocrine therapy (NET), there is a need for reliable biomarkers that can identify HR+ HER2- tumors who are likely to benefit from NET. NBRST (NCT01479101) compared the prognostic value of 70-gene risk classification and 80-gene molecular subtyping signatures conventional pathological methods in response therapy. We evaluated association these clinical 5-year outcome treated NET.1091 scheduled were prospectively enrolled...
Mammary duct ectasia is a rare finding in males. We report case of mammary 58 year old male with liver failure and end stage renal failure. discuss radiology findings as well potential risk factors management options for symptomatic ectasia.
e24229 Background: Compared with breast invasive ductal carcinoma (IDC), lobular (ILC) has been shown to be more strongly associated risk factors that modulate hormone levels, including lifestyle such as obesity. We evaluated the effect of metabolic syndrome (MS) in patients ILC vs. IDC histopathological tumor types using transcriptome gene expression analysis (GEA) and pathway analyses. Methods: This subanalysis included 492 from PROMIS IMPACt studies for whom characteristics were captured...
Abstract Background: The PROMIS trial (NCT01617954) previously showed that an OncotypeDx (ODx) Intermediate Recurrence Score (RS 18-30) led to uncertainty in prescribing chemotherapy (CT), especially the middle of intermediate range from RS 21-26 where equal number patients were recommended receive and forego CT (Tsai, JAMA Oncology 2018). Forty-seven percent (3183/6711) randomized TAILORx classified as 18-25 are well represented PROMIS. These with may still lack definitive recommendation...
Abstract Background: Invasive lobular carcinoma (ILC) of the breast has been shown to be more strongly associated with risk factors that modulate hormone levels, including obesity, as compared invasive ductal (IDC). Our previous study indicated biology disease engages disparately for ILC and IDC. This further evaluated effect metabolic syndrome (MS) in patients histopathological tumor types using whole transcriptome gene expression (GEA) pathway analyses. Methods: analysis included 76 from...
Purpose: A 65-year-old female presented with a complaint of back and abdominal pain, nausea vomiting for two days. Her past medical history was significant hypertension hypothyroidism no previous surgery. Methods: Significant lab values: WBC 27, Na 122, K 6.6, creat 11.2 lipase 1290. LFTs amylase were normal. CT scan the abdomen pelvis, w/o contrast, revealed dilated proximal small bowel loops, collapsed distal loops cholelithiasis. She admitted diagnosis obstruction versus pancreatitis. NGT...
Abstract Background: The PROMIS trial (NCT01617954) previously evaluated how a definitive result from the MammaPrint 70-gene signature (70-GS) can impact treatment recommendations for patients with an intermediate range recurrence score (RS 18-30) 21-gene assay (21-GA, Oncotype DX). Since publication of this study, TAILORx results published in 2018 (and further explored June 2019) suggested interaction between 21-GA, patient age (≤50 yrs), and clinical risk. Initially, chemotherapy (CT) was...